Blood cell deficiency treatment method

A compound of formula V

• 117
• or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof,
• wherein
• (a) R1 and R2 are each independently selected from the group consisting of a hydrogen atom and a glucuronide group having the formula
• 118
• wherein (i) R7 is an alkyl ester wherein the alkyl moiety is optionally substituted, and (ii) R8, R9 and R10 are each —OR14, wherein R14 is a hydrogen atom or a protected hydroxy, optionally substituted alkyl, cycloalkyl;
• and (iii) at least one of R1 or R2 is not hydrogen;
• (b) R5 and R6 are each independently selected from the group consisting of a hydrogen atom, optionally substituted alkyl, hydroxy, and a protected hydroxy;
• or R5 and R6 taken together are a ketone group (═O);
• and
• (c) R12 and R13 are each independently selected from the group consisting of a hydrogen atom, optionally substituted alkyl, hydroxy, and a protected hydroxy.

A compound of formula VII

• 119
• or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof,
• wherein
• (a) R3 and R4 are each independently selected from the group consisting of a hydrogen atom and a glucuronide group having the formula
• 120
• wherein (i) R7 is an alkyl ester wherein the alkyl moiety is optionally substituted, and (ii) R8, R9 and R10 are each —OR14, wherein R14 is a hydrogen atom, optionally substituted alkyl, cycloalkyl, or a protected hydroxy;
• and (iii) at least one of R3 and R4 is not hydrogen;
• (b) R5 and R6 are each independently selected from the group consisting of a hydrogen atom, optionally substituted alkyl, hydroxy, and a protected hydroxy;
• or R5 and R6 taken together are ═O;
• (c) R11 is a hydrogen atom or a protected hydroxy;
• and
• (d) R12 and R13 are each independently selected from the group consisting of a hydrogen atom, optionally substituted alkyl, hydroxy, and a protected hydroxy.

A compound of formula IX

• 121
• or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof,
• wherein (a) R1 and R2 are each independently selected from the group consisting of a hydrogen atom and —O—C(O)—OR14,
• wherein (i) R14 is selected from the group consisting of a hydrogen atom, optionally substituted alkyl, and carbocyclic ring (cycloalkyl);
• and (ii) at least one of R1 or R2 is not hydrogen;
• (b) R5, R6, R7, and R8 are each independently selected from the group consisting of a hydrogen atom, optionally substituted alkyl, hydroxy, —O—C(O)—OR14, and a protected hydroxy;
• or R5 and R6 taken together form an oxygen atom, which, together with the carbon atom to which R5 and R6 are joined, forms a ketone group;
• or R7 and R8 taken together form an oxygen atom, which, together with the carbon atom to which R7 and R8 are joined, forms a ketone group;
• and
• (c) R12 and R13 are each independently selected from the group consisting of a hydrogen atom, optionally substituted alkyl, hydroxy, and a protected hydroxy.

A method to treat a symptom or condition associated with one or more delayed adverse or unwanted effects of radiation exposure in a subject in need thereof comprising administering to the subject, or delivering to the subject's tissues, an effective amount of a compound of formula 1

• 122
• wherein, each R1, R2, R3, R4, R5, R6and R10 independently are —H, —OH, —ORPR, —SRPR, —N(RPR)2, —O—Si—(R13)3, —CHO, —CHS, —CH═NH, —CN, —SCN, —NO2, —OSO3H, —OPO3H, an ester, a thioester, a thionoester, a phosphoester, a phosphothioester, a phosphonoester, a phosphiniester, a sulfite ester, a sulfate ester, an amide, an amino acid, a peptide, an ether, a thioether, an acyl group, a thioacyl group, a carbonate, a carbamate, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heteroaryl moiety, an optionally substituted heterocycle, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer, or,
• one or more of both R1, R2, R3 or R4 together comprise an independently selected spiro ring, or
• one more of R1, R2, R3, R4, R5, R6 and R10 independently are ═O, ═S, ═N—OH, ═CH2, or a spiro ring, and the hydrogen atom or the second variable group that is bonded to the same carbon atom is absent, or,
• one or more of two adjacent R1—R6 and R10 comprise an independently selected acetal, thioacetal, ketal or thioketal moiety;
• all R3 and R4 together comprise a structure of formula 2
• 123
• R is —C(R10)2—, —C(R10)2—C(R10)2—, —C(R10)2—C(R10)2—C(R10)2—, —C(R10)2—O—C(R10)2—, —C(R10)2—S—C(R10)2—, —C(R10)2—NRPR—C(R10)2—, —O—, —O—C(R10)2—, —S—, —S—C(R10)2—, —NRPR or —NRPR—C(R10)2—;
• R8 and R9 independently are —C(R10)2—, —C(R10)2—C(R10)2—, —O—, —O—C(R10)2—, —S—, —S—C(R10)2—, —NRPR— or —NRPR—C(R10)2—, or one or both of R8 or R9 independently are absent, leaving a 5-membered ring;
• R13 independently is C1-6 alkyl;
• RPR independently is —H or a protecting group;
• D is a heterocycle or a 4-, 5-, 6- or 7-membered ring that comprises saturated carbon atoms, wherein 1, 2 or 3 ring carbon atoms of the 4-, 5-, 6- or 7-membered ring are optionally independently substituted with —O—, —S— or —NRPR— or where 1, 2 or 3 hydrogen atoms of the heterocycle or where 1, 2 or 3 hydrogen atoms of the 4-, 5-, 6- or 7-membered ring are independently substituted with —OH, —ORPR, —SRPR, —N(RPR)2, —O—Si—(R13)3, —CHO, —CHS, —CH═NH, —CN, —SCN, —NO2, —OSO3H, —OPO3H, an ester, a thioester, a thionoester, a phosphoester, a phosphothioester, a phosphiniester, a sulfite ester, a sulfate ester, an amide, an amino acid, a peptide, an ether, a thioether, an acyl group, a thioacyl group, a carbonate, a carbamate, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heteroaryl moiety, an optionally substituted heterocycle, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide or a polymer, or,
• one more of the ring carbons are substituted with ═O, ═S, ═N—OH, ═CH2, or a spiro ring, or
• two adjacent D ring carbons comprise an independently selected acetal, thioacetal, ketal or thioketal moiety, or
• D comprises two 5- or 6-membered rings, wherein the rings are fused or are linked by 1 or 2 bonds, and the dotted lines are optional double bonds, provided that there are not double bonds simultaneously at the 4-5 and the 5-6 positions.
• wherein the formula 1 compound is administered or delivered to the subject's tissues beginning at least 1 day after the subject has been exposed to a dose of radiation that will cause or could potentially cause the one or more delayed adverse or unwanted effects of the radiation exposure or
• wherein the formula 1 compound is administered or delivered to the subject's tissues beginning at least 1 day after the subject has been exposed to at least one subdose of a planned course of radiation exposures that will cause or could potentially cause the one or more delayed adverse effects or unwanted effects of the radiation exposure.